Topic
16 stories from Planck Standard. Latest: July 20, 2026.
Biogen's diranersen missed its main goal in a Phase 2 trial but reduced tau pathology and showed signs of slowing decline, enough to push it toward a Phase 3 study.
In a randomized study of adults living with HIV, semaglutide cut the pace of biological aging by 9%, the first clinical hint the blockbuster drug may touch aging itself.
Finerenone slowed kidney decline and cut the risk of heart failure and death across a far wider group of patients than it is prescribed for today — results published simultaneously in The Lancet, NEJM and JAMA.
Cambridge researchers and spin-out DIOSynVax report that a vaccine whose key component was designed entirely by machine learning was safe in 39 volunteers and triggered immunity against SARS-CoV-2, SARS-CoV-1 and bat coronaviruses.
New drug daraxonrasib reduces death risk by 60% in clinical trial, offering hope for patients with one of medicine's deadliest cancers.
A King's College London study found that 12 months of abatacept kept high-risk patients from developing rheumatoid arthritis long after treatment ended, pointing toward a future of preventing the disease rather than just treating it.
Akeso and Summit Therapeutics report breakthrough results for ivonescimab in late-stage study, potentially offering new hope for patients with advanced lung cancer.
Eli Lilly's retatrutide injection shows results comparable to gastric bypass surgery among heaviest patients after 80 weeks of treatment.
Adults with stage 1 hypertension who practiced baduanjin, a gentle 800-year-old mind-body routine, experienced meaningful blood pressure reductions that lasted for an entire year.
Adults with stage 1 hypertension who practiced baduanjin saw meaningful drops in blood pressure within three months that lasted for an entire year.
Lubiprostone appears to slow kidney function decline in patients with moderate chronic kidney disease by improving gut bacteria.
Clinical trial finds lubiprostone may slow chronic kidney disease by changing gut bacteria that boost spermidine production.
Clinical trial of 150 patients reveals lubiprostone preserves kidney function by boosting gut bacteria that produce protective compounds, opening new treatment pathways.
Baxdrostat reduces blood pressure by nearly 10 mmHg in patients with treatment-resistant hypertension, targeting hormone that causes salt retention.
Groundbreaking study shows all ten patients, from toddlers to young adults, experienced improved hearing after receiving working copy of OTOF gene.
Rockefeller University's redesigned CD40 therapy achieved complete remission in two of 12 patients with metastatic cancer